At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 53 enrolled
Drug / intervention
Neurexan +1 moredrug
Likely dose
Neurexan 0.6 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Neuronal Correlates of Neurexan® Action in Mildly to Moderately Stressed Probands - A Randomized, Placebo-controlled, Double-blind, Cross-over Trial of Mode of Action and Response Prediction by Functional Magnetic Resonance Imaging MRI
In Brief
A Phase 2 clinical trial evaluating Neurexan and Placebo for Acute Stress Reaction. Completed, enrolled 53 participants across 1 site.
Detailed Summary
The purpose of this study is to explore the effect of Neurexan® on the brain response when participants undergo an emotional stressful condition in verum compared to placebo.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAcute Stress Reaction
CountriesGermany
Collaborators--
Timeline
Phase 2CompletedFinished
20162017201820192020202120222023202420252026
Enrollment StartAug 2015
First PostedNov 2015
Primary CompletionDec 2015
TodayJul 2026
First PostedNov 11, 2015
Enrollment StartAug 1, 2015
Primary CompletionDec 1, 2015
TodayJul 2, 2026
Enrollment to primary: 4 monthsPosted 10.6 years ago
Interventions
Neurexandrug
0.6 mg / tablet
Placebodrug
Neurexan-matched Placebo tablet